Glycosylated 18β-glycyrrhetinic acid derivatives as promising inhibitors of the SARS-CoV-2 main protease

Q: What type of study is this?

This is a Experimental Study study.

Eric C. Liao; Shen-Chieh Chou; Tzu-Yu Huang; Sheng-Cih Huang; Ting Yu; Feng‐Pai Chou; Tung‐Kung Wu

doi:10.1039/d5ra04664e

January 1, 2025RSC AdvancesOpen Access

Glycosylated 18β-glycyrrhetinic acid derivatives as promising inhibitors of the SARS-CoV-2 main protease

View Full Paper

Ask AI

Bookmark

Share

Key Points

These glycosylated compounds effectively inhibit the SARS-CoV-2 main protease, offering new treatment options.
Inhibition is enhanced by unique sugar-driven binding, improving solubility, and demonstrating efficacy.
The research demonstrates glycosylated compounds as promising and cost-effective antiviral candidates against COVID-19.
Novel derivatives of 18β-glycyrrhetinic acid show significant antiviral activity, warranting further investigation.

Implication

Glycosylated derivatives inhibit SARS-CoV-2 main protease, suggesting their potential as antiviral candidates.

Abstract

Enzymatically glycosylated 18β-glycyrrhetinic acid derivatives potently inhibit SARS-CoV-2 M pro , with enhanced solubility and unique sugar-driving binding, highlighting their potential as cost-effective antiviral candidates.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Liao et al. (2025) studied this question.

synapsesocial.com/papers/68d44b3031b076d99fa54931 https://doi.org/10.1039/d5ra04664e

View Full Paper

Ask AI

Bookmark

Share

Glycosylated 18β-glycyrrhetinic acid derivatives as promising inhibitors of the SARS-CoV-2 main protease

Key Points

Implication

Abstract

Discussion

Cite This Study

Glycosylated 18β-glycyrrhetinic acid derivatives as promising inhibitors of the SARS-CoV-2 main protease

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading